(3R,4S,5R,6R)-4-[(2R,3R,4S,5R,6R)-3,5-Dihydroxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol

Term ID

CHEBI:148574

Synonyms

alpha-D-gluco-hexopyranosyl-(1->3)-[alpha-D-gluco-hexopyranosyl-(1->6)]-alpha-D-gluco-hexopyranosyl-(1->3)-D-gluco-hexopyranose
Glc(a1-3)[Glc(a1-6)]Glc(a1-3)Glc
WURCS=2.0/2,4,3/[a2122h-1x_1-5][a2122h-1a_1-5]/1-2-2-2/a3-b1_b3-c1_b6-d1

Definition

References

GlyGen:G25938VQ
GlyTouCan:G25938VQ

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from (3R,4S,5R,6R)-4-[(2R,3R,4S,5R,6R)-3,5-Dihydroxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol

Phenotype where environments contain (3R,4S,5R,6R)-4-[(2R,3R,4S,5R,6R)-3,5-Dihydroxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol

Phenotype modified by environments containing (3R,4S,5R,6R)-4-[(2R,3R,4S,5R,6R)-3,5-Dihydroxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol

Phenotype affecting (3R,4S,5R,6R)-4-[(2R,3R,4S,5R,6R)-3,5-Dihydroxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol

Human Disease Model